NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ADTX

Aditxt Inc

Jun 30 • 04:00PM ET

1.28

Dollar change -0.05
Percentage change -3.76	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX SAVA INO ALT VXRT AIM PDSB AYTU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-69702.52	Insider Own	0.00%	Shs Outstand	2.43M	Perf Week	-4.48%
Market Cap	3.11M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	2.43M	Perf Month	-20.99%
Enterprise Value	5.87M	PEG	-	EPS next Q	-	Inst Own	2.37%	Short Float	1.01%	Perf Quarter	-74.40%
Income	-31.33M	P/S	51.83	EPS this Y	-	Inst Trans	0.06%	Short Ratio	0.04	Perf Half Y	-97.22%
Sales	0.06M	P/B	0.09	EPS next Y	-	ROA	-85.91%	Short Interest	0.02M	Perf YTD	-97.30%
Book/sh	13.73	P/C	6.48	EPS next 5Y	-	ROE	-191.76%	52W High	27200.00 -100.00%	Perf Year	-99.99%
Cash/sh	0.20	P/FCF	-	EPS past 3/5Y	96.02% 83.15%	ROIC	-185.78%	52W Low	1.28 0.00%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.45% -	Gross Margin	-1897.68%	Volatility	23.93% 11.67%	Perf 5Y	-
Dividend TTM	-	EV/Sales	97.83	EPS Y/Y TTM	93.24%	Oper. Margin	-39651.08%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.08	Sales Y/Y TTM	-89.08%	Profit Margin	-56638.43%	RSI (14)	36.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.08	EPS Q/Q	99.99%	SMA20	-10.88%	Beta	1.33	Target Price	610000.00
Payout	-	Debt/Eq	0.25	Sales Q/Q	-98.72%	SMA50	-26.42%	Rel Volume	0.44	Prev Close	1.33
Employees	26	LT Debt/Eq	0.02	Earnings	-	SMA200	-99.57%	Avg Volume	635.38K	Price	1.28
IPO	Jun 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- 120.59%	Trades		Volume	292,021	Change	-3.76%

Jun-26-25 08:15AM	Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET (Business Wire)
Jun-09-25 08:15AM	Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors (Business Wire)
Jun-05-25 08:15AM	Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 (Business Wire) -7.69%
May-19-25 08:00AM	Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. (GlobeNewswire) +5.42%
08:00AM	Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics (Business Wire)
09:00AM	Loading…
May-02-25 09:00AM	Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt, and Dr. Friedrich Kapp, Co-CEO of Adimune, to Discuss Progress of Lead Therapeutic Candidate ADI-100 (Business Wire)
Apr-17-25 09:08PM	KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) +13.64% -10.80%
09:03PM	KILL Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
08:15AM	Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
Apr-16-25 08:15AM	Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 (Business Wire) -8.71%
Apr-14-25 08:15AM	Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) -13.19%
Apr-11-25 08:15AM	Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements (Business Wire)
Apr-10-25 09:24AM	Why Aditxt Inc. (ADTX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements (Business Wire) -8.81%
Apr-02-25 08:17AM	Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 (GlobeNewswire) +10.62%
08:15AM	Loading…
08:15AM	Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 (Business Wire)
Mar-28-25 08:15AM	Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection (Business Wire) -18.90%
Mar-24-25 08:30AM	Evofem Reports Fourth Consecutive Year of Net Sales Growth (PR Newswire) -25.55%
08:15AM	Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk (Business Wire)
Mar-18-25 07:22AM	Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update (GlobeNewswire) +71.62%
Mar-17-25 08:15AM	Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025 (Business Wire) -13.03%
Mar-12-25 04:15PM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025 (Business Wire) -5.33% -41.20%
Mar-06-25 08:15AM	Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S. (Business Wire) -13.30%
Feb-22-25 08:45AM	Aditxt subsidiary Persanta engages Dominary Securities for IPO (TipRanks)
Feb-21-25 08:15AM	Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 (Business Wire) -22.98%
Feb-13-25 08:15AM	Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time (Business Wire) -17.87%
Jan-13-25 08:15AM	Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform (Business Wire) -8.24%
Dec-12-24 08:15AM	Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials (Business Wire)
Nov-19-24 07:17AM	Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. (GlobeNewswire)
Nov-14-24 04:36PM	Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 (PR Newswire) -7.32%
07:15AM	Loading…
07:15AM	Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 (GlobeNewswire)
Nov-08-24 08:30AM	Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares (Business Wire)
Nov-07-24 08:30AM	Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders (Business Wire) -22.11%
Nov-06-24 05:55PM	Appili Therapeutics Announces Results of Special Meeting of Shareholders (GlobeNewswire)
08:30AM	Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem (Business Wire)
08:00AM	Evofem Secures Investor Support for Proposed Merger through Voting Agreements (PR Newswire)
Oct-31-24 08:30AM	Aditxts Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (Business Wire)
07:15AM	Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (GlobeNewswire)
Oct-30-24 05:00PM	Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time (Business Wire) -5.84%
Oct-29-24 08:15AM	Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives (Business Wire) -18.07%
Oct-28-24 08:15AM	Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem (Business Wire) -14.72%
Oct-21-24 08:15AM	Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time (Business Wire)
Oct-12-24 05:28PM	Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy (TipRanks)
Oct-10-24 08:15AM	Aditxts Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appilis Shareholder Approval (Business Wire)
Oct-09-24 10:52AM	Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time (Business Wire) -14.18%
Oct-08-24 08:15AM	Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem (Business Wire) -5.37%
Oct-03-24 08:15AM	Aditxt Delivers Shareholder Update and 2024 Year-End Plan (Business Wire) -28.15%
Sep-27-24 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 (Business Wire) -25.60%
Sep-24-24 08:15AM	Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt (Business Wire) -15.87%
Sep-20-24 08:15AM	Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 (Business Wire)
Sep-09-24 08:15AM	Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 (Business Wire)
Sep-04-24 08:15AM	Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients (Business Wire) -19.68%
Aug-29-24 08:15AM	Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 (Business Wire) -7.64%
Aug-26-24 08:15AM	Aditxts Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic Endometriosis Test (MET) and Mitomic Prostate Test (MPT) (Business Wire) -11.70%
Aug-21-24 08:15AM	Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics (Business Wire)
Aug-20-24 08:17AM	Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution (PR Newswire) -16.67%
Aug-14-24 07:00AM	Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 (PR Newswire)
Aug-13-24 08:15AM	Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans (Business Wire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -11.38%
Aug-09-24 04:15PM	Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
08:00AM	Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
Aug-07-24 08:15AM	Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer (Business Wire) +29.39%
Jul-25-24 09:00AM	Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st (GlobeNewswire)
08:30AM	Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition (Business Wire)
Jul-23-24 08:47AM	Evofem Signs Phexxi License Agreement for Middle East with Pharma 1 (PR Newswire) +5.71%
Jul-17-24 06:30AM	Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing (Business Wire) +45.01%
Jul-15-24 07:20AM	Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC (PR Newswire) -6.21%
Jun-27-24 08:36AM	Hello Alpha Partners with Evofem to Offer Phexxi as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare (PR Newswire)
Jun-11-24 08:36AM	Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter (PR Newswire)
May-20-24 10:53PM	ADTX Stock Earnings: Aditxt Reported Results for Q1 2024 (InvestorPlace)
May-15-24 06:50AM	Evofem Biosciences Announces Financial Results for the First Quarter of 2024 (PR Newswire) -6.82%
May-03-24 02:14PM	CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) -6.88%
09:00AM	Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire)
Apr-02-24 08:30AM	Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) (Business Wire) +5.97%
07:30AM	Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc. (GlobeNewswire)
Mar-27-24 08:36AM	Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 (PR Newswire)
Mar-20-24 08:54AM	Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment' Contraceptive PHEXXI with Medi-Cal (PR Newswire) +5.25%
Mar-07-24 07:54AM	For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy (PR Newswire) +13.51%
Feb-01-24 08:00AM	Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 (PR Newswire)
Jan-30-24 08:30AM	Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications (Business Wire)
Jan-08-24 08:30AM	Aditxt, Inc.s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million (Business Wire)
Jan-05-24 08:30AM	Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire)
Jan-02-24 08:30AM	Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire) -27.60%
Dec-29-23 05:07PM	Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) +37.55%
Dec-12-23 11:20AM	Why Is Aditxt (ADTX) Stock Up 58% Today? (InvestorPlace) +60.26%
08:30AM	Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally (Business Wire)
Nov-30-23 07:39AM	Why Is Aditxt (ADTX) Stock Up 70% Today? (InvestorPlace) +13.43%
Oct-06-23 08:00AM	Aditxt, Inc. to Present at 8th Annual Dawson James Conference (GlobeNewswire)
Oct-05-23 08:00AM	Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-08-23 07:05AM	Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023 (Business Wire)
Sep-06-23 04:30PM	Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) -10.46% -10.68%
Aug-31-23 07:00PM	Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) +461.22% -24.80%
Aug-18-23 07:02AM	Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale (Business Wire) +5.76%
Aug-17-23 04:12PM	CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023 (Business Wire) +31.50%
Jun-20-23 07:49AM	Aditxt, Inc.s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics (Business Wire)
May-19-23 06:10AM	Aditxt First Quarter 2023 Earnings: US$1.31 loss per share (vs US$6.80 loss in 1Q 2022) (Simply Wall St.)
May-05-23 07:05AM	Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome (Business Wire)
Apr-24-23 04:15PM	Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) -8.51%
Apr-20-23 01:35PM	Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) +17.44%

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRT FINANCIAL LP	10% Owner	Oct 15 '24	Buy	1.50	15,636	23,454	25,434	Oct 17 01:58 PM
HRT FINANCIAL LP	10% Owner	Oct 16 '24	Sale	1.17	25,534	29,875	0	Oct 17 01:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADTX

Aditxt Inc

Upgrade your FINVIZ experience